相关实验视频
Updated: Jul 15, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
打破模具:克服对免疫检查点抑制剂的耐药性
Menglu Zhao1, Chun-Yan Yan1, Ya-Nan Wei1
1Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang, 110022, PR China.
免疫检查点抑制剂 (ICI) 在癌症治疗中表现有前途,但面临药物耐药性. 本综述探讨了耐药性机制,并提出了组合疗法,以改善化疗耐药癌症的结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 癌症研究 癌症研究
背景情况:
- 免疫检查点阻塞疗法,包括PD-1/PD-L1抑制剂,对各种癌症有效.
- 耐药性仍然是一个重大挑战,限制了这些治疗的有效性.
研究的目的:
- 阐明PD-1/PD-L1抑制剂诱导的药物耐受性机制.
- 概述基于机制的组合疗法和针对内在免疫和免疫检查点的小分子药物.
主要方法:
- 对免疫检查点抑制剂和耐药性研究的文献综述.
- 分析导致PD-1/PD-L1抑制剂耐受性的机制.
- 识别潜在的组合策略和小分子标.
主要成果:
- 对PD-1/PD-L1抑制剂的耐药性是由复杂的机制驱动的.
- 针对内在免疫和免疫检查点的组合疗法显示出潜力.
- 个性化治疗优化对于提高疗效至关重要.
结论:
- 了解抵抗机制是克服ICI不响应的关键.
- 新的组合策略和小分子药物为治疗耐化疗癌症提供了新的途径.
- 个性化的方法可以改善PD-1/PD-L1介导的免疫调节,并减少耐药性.
更多相关视频
09:01Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
相关概念视频
Tumor Immunotherapy
Treatment Resistant Cancers
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cell-mediated Immune Responses
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...